EXCERPT:
WuXi Biologics recorded a record number of new projects in 2025, with US clients accounting for a disproportionate share — a notable data point given the ongoing geopolitical and legislative pressure on the company’s US business.
CONTENT:
WuXi Biologics reported a record number of new project wins in 2025, with US-based clients making up a significant portion of that intake — a striking figure given the sustained legislative and geopolitical scrutiny the company has faced in Washington.
The BIOSECURE Act, which would restrict US government-funded entities from contracting with certain Chinese biotechs including WuXi, has created real uncertainty for sponsors with WuXi in their supply chains. Yet the project numbers suggest that commercial sponsors — particularly smaller biotechs without government funding dependencies — have continued engaging WuXi for its cost and capacity advantages.
For CROs and CDMOs competing in the biologics manufacturing space, this dynamic is worth tracking. Regulatory and geopolitical risk is now a legitimate factor in CMO selection conversations, and sponsors are increasingly asking service providers to articulate their risk profile alongside their technical capabilities.